Cabaser Pfizer

Other name: Cabergoline

Manufacturer: Pharmacia & Upjohn (Pfizer)

Pharmaceutical n ame: Cabergoline

Pack: 1mg, 1tab.





The pharmacokinetic and metabolic profiles of Cabaser have been studied in healthy volunteers of both sexes, in female hyperprolactinemic patients and in parkinsonian patients. After oral administration of the labelled compound, radioactivity was rapidly absorbed from the gastrointestinal tract as the peak of radioactivity in plasma was between 0.5 and 4 hours. Ten days after administration about 18/20% and 55/72% of the radioactive dose (3H-cabergoline/14C-cabergoline) was recovered in urine and faeces, respectively.

The low urinary excretion of unchanged Cabaser has been confirmed also in studies with non-radioactive product. The elimination half-life of Cabaser, estimated from urinary excretion rates, is long (63-68 hours in healthy volunteers, 79-115 hours in hyperprolactinemic patients).

Food does not appear to affect absorption and disposition of Cabaser. Since the tolerability of dopaminergic agents is improved when administered with food, it is recommended that Cabaser be taken with meals.